TYK2 Inhibitors May Need Little Lab Monitoring in Psoriasis, Lebwohl Says
Newer oral TYK2 inhibitors beat apremilast and deucravacitinib, and deucravacitinib's clean blood-work record suggests minimal lab monitoring ahead, says Mount Sinai's Mark Lebwohl, MD.
